Aciont® To Present on VisulexTM Technologies at the 4th Ocular & Drug Discovery Conference

Salt Lake City, UT, January 12, 2012 --( Aciont Inc. announced today that both Kongnara Papangkorn, Research Director and Sarah Abdulla Molokhia, Scientific Research Consultant, will present on Aciont’s Visulex technologies at the Global Technology Community’s 4th Ocular & Drug Discovery Conference, February 27-28, 2012, in Las Vegas, NV. The Visulex system aims to eliminate frequent, painful injections to the eye while improving patient experience, ease of use, and accessibility to treatments currently on the market. The patient-friendly drug delivery applicator allows for treatment by nurses or potentially patients themselves.

Dr. Papangkorn’s presentation is entitled, “A Non-Invasive Topical Application Device for Treatment of Intermediate and Posterior Segment Eye Diseases.” The presentation discusses Aciont’s passive diffusion-based ocular drug delivery system (Visulex-P) and its potential to improve treatment of certain serious eye diseases such as intermediate and posterior uveitis.

Dr. Molokhia’s presentation is entitled, “Transscleral Iontophoresis for Macromolecules,” which will discuss the success of in vivo macromolecule delivery to the posterior eye tissues using iontophoresis (a mild electrical field). The device (Visulex-I) has shown promising results during in vitro and in vivo pharmacokinetics studies as well as in vivo real time magnetic resonance imaging studies. “Our research demonstrates the ability for Visulex-I to deliver drug amounts within the same order of magnitude reported using intravitreal injections, potentially revolutionizing the treatment of sight-threatening diseases, particularly age-related macular degeneration,” explains Dr. Molokhia.

Program note: John Higuchi, Aciont’s CEO, may substitute as the presenter on behalf of Dr. Molokhia in the event she is unable to attend the conference. Information about the conference can be found through this website link:


Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic), controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont’s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont is located in Salt Lake City, Utah. For more information, visit the company’s website at

Source: Aciont Inc.
Aciont Inc
Jillian Conrad